Search
ALTU-135
go.drugbank.com/drugs/DB05330InvestigationalALTU-135 has been granted orphan drug and fast-track designation as well as CMA Pilot 2 program status by the Food and Drug Administration (FDA). … ALTU-135, the Company's orally administered enzyme replacement therapy for patients with pancreatic insufficiency, is manufactured by blending three drug substance enzymes: lipase, protease and amylase
Acetylcysteine
go.drugbank.com/drugs/DB06151ApprovedInvestigationalAcetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results. Ac...
Mibefradil
go.drugbank.com/drugs/DB01388ApprovedWithdrawnMibefradil was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.
PRO 2000
go.drugbank.com/drugs/DB05385InvestigationalPRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials.
Human interferon omega-1
go.drugbank.com/drugs/DB05472InvestigationalIt occurs naturally in the human body and is currently being manufactured by Intarcia through genetic engineering.
Tubercidin
go.drugbank.com/drugs/DB03172ExperimentalAn antibiotic purine ribonucleoside that readily substitutes for adenosine in the biological system, but its incorporation into DNA and RNA has an inhibitory effect on the metabolism of these nucleic acids
Umifenovir
go.drugbank.com/drugs/DB13609Investigational[A191475] Umifenovir is currently being investigated as a potential treatment and prophylactic agent for COVID-19 caused by SARS-CoV2 infections in combination with both currently available and investigational
Talc
go.drugbank.com/drugs/DB09511ApprovedInvestigationalIn fact, recent studies have reported that talc increases the risk of ovarian and endometrial cancers by approximately 30 percent.
Nefazodone
go.drugbank.com/drugs/DB01149ApprovedWithdrawnNefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb.
Bromelains
go.drugbank.com/drugs/DB13281ApprovedInvestigationalIt works by selectively inhibiting the biosynthesis of proinflammatory prostaglandins [A27197] and also has analgesic properties, as well as anticancerous and pro-apoptotic effects.